Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

ATNM

Actinium Pharmaceuticals, Inc.

Tremor tracks 2 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

  • ATNMActinium Pharmaceuticals
    10Calm

    Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

    Running, no new patientsPhase 3153 patientsMain results: Jun 2022
  • ATNMActinium Pharmaceuticals
    0Calm

    Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

    Not started yetPhase 2/3306 patientsMain results: Feb 2029

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

0 sales (0 not pre-planned) · 0 purchases

No insider sales or purchases in the last 6 months.

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

  • An executive or board member joined or left; Shared information with investorsNews report (8-K)Oct 15, 2026
  • Warning about being removed from the stock exchange; Shared information with investorsNews report (8-K)Aug 14, 2026
  • Quarterly reportQuarterly report (10-Q)Aug 7, 2026
  • Other newsNews report (8-K)Jun 18, 2026
  • Warning about being removed from the stock exchange; Shared information with investorsNews report (8-K)May 29, 2026

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.